secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2024-09-11T23:59:59+00:00
Accession:  0001193125-24-217229
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio CMO Trishna Goswami steps down effective Sept 6, 2024
------------------------------------------------------------

- Dr. Goswami and company mutually agreed to her departure as Chief Medical Officer.
- Separation agreement provides two months' base salary cash severance.
- Agreement includes general release, non-disparagement, confidentiality, and cooperation covenants.
- Full separation agreement to be filed as exhibit to Q3 2024 10-Q.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312524217229/0001193125-24-217229-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312524217229/d853919d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-217229

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer